Inhibition of poly(ADP-ribose) pollyrnerase in cancer

被引：87

作者：

Plummer, Elizabeth Ruth ^{[1
]}

机构：

[1] Univ Newcastle, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

来源：

CURRENT OPINION IN PHARMACOLOGY | 2006年 / 6卷 / 04期

关键词：

D O I：

10.1016/j.coph.2006.02.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited.

引用

页码：364 / 368

页数：5

共 43 条

[1] ENDOGENOUS MUTAGENS AND THE CAUSES OF AGING AND CANCER [J].

AMES, BN ;

GOLD, LS .

MUTATION RESEARCH, 1991, 250 (1-2) :3-16

[2] Oh what a tangled web it weaves: BRCA1 and DNA decatenation [J].

Ashworth, A .

CANCER CELL, 2005, 8 (02) :95-97

[3] Repair and genetic consequences of endogenous DNA base damage in mammalian cells [J].

Barnes, DE ;

Lindahl, T .

ANNUAL REVIEW OF GENETICS, 2004, 38 :445-476

[4] Poly(ADP-ribosyl)ation inhibitors:: Promising drug candidates for a wide variety of pathophysiologic conditions [J].

Beneke, S ;

Diefenbach, J ;

Bürkle, A .

INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (06) :813-818

[5] DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis [J].

Bernstein, C ;

Bernstein, H ;

Payne, CM ;

Garewal, H .

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2002, 511 (02) :145-178

[6] POTENTIATION OF TEMOZOLOMIDE-INDUCED CYTOTOXICITY - A COMPARATIVE-STUDY OF THE BIOLOGICAL EFFECTS OF POLY(ADP-RIBOSE) POLYMERASE INHIBITORS [J].

BOULTON, S ;

PEMBERTON, LC ;

PORTEOUS, JK ;

CURTIN, NJ ;

GRIFFIN, RJ ;

GOLDING, BT ;

DURKACZ, BW .

BRITISH JOURNAL OF CANCER, 1995, 72 (04) :849-856

[7] Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro [J].

Bowman, KJ ;

Newell, DR ;

Calvert, AH ;

Curtin, NJ .

BRITISH JOURNAL OF CANCER, 2001, 84 (01) :106-112

[8] Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064 [J].

Bowman, KJ ;

White, A ;

Golding, BT ;

Griffin, RJ ;

Curtin, NJ .

BRITISH JOURNAL OF CANCER, 1998, 78 (10) :1269-1277

[9] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[10] Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361 [J].

Calabrese, CR ;

Almassy, R ;

Barton, S ;

Batey, MA ;

Calvert, AH ;

Canan-Koch, S ;

Durkacz, BW ;

Hostomsky, Z ;

Kumpf, RA ;

Kyle, S ;

Li, J ;

Maegley, K ;

Newell, DR ;

Notarianni, E ;

Stratford, IJ ;

Skalitzky, D ;

Thomas, HD ;

Wang, LZ ;

Webber, SE ;

Williams, KJ ;

Curtin, NJ .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (01) :56-67

← 1 2 3 4 5 →